[1]曾丹丹,何英聪.糖皮质激素联合特布他林雾化治疗慢阻肺急性加重期患者的疗效及对炎症因子、肺功能的影响[J].医学信息,2022,35(23):129-132.[doi:10.3969/j.issn.1006-1959.2022.23.026]
　ZENG Dan-dan,HE Ying-cong.Effect of Glucocorticoid Combined with Terbutaline Atomization on Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and its Effect on Inflammatory Factors and Lung Function[J].Journal of Medical Information,2022,35(23):129-132.[doi:10.3969/j.issn.1006-1959.2022.23.026]
点击复制

糖皮质激素联合特布他林雾化治疗慢阻肺急性加重期患者的疗效及对炎症因子、肺功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
129-132
栏目:
药物与临床
出版日期:
2022-12-01

文章信息/Info

Title:
Effect of Glucocorticoid Combined with Terbutaline Atomization on Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and its Effect on Inflammatory Factors and Lung Function
文章编号:
1006-1959（2022）23-0129-04
作者:
曾丹丹; 何英聪
（石城县人民医院呼吸内科1，输血科2，江西 石城 342700）
Author(s):
ZENG Dan-dan; HE Ying-cong
(Department of Respiratory1,Department of Blood Transfusion2,Shicheng County People’s Hospital,Shicheng 342700,Jiangxi,China)
关键词:
糖皮质激素; 特布他林; 慢阻肺急性加重期; 炎症因子; 肺功能
Keywords:
Glucocorticoids; Terbutaline; Acute exacerbation of chronic obstructive pulmonary disease; Inflammatory factors; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2022.23.026
文献标志码:
A
摘要:
目的 研究糖皮质激素联合特布他林雾化治疗慢阻肺急性加重期患者的疗效及对患者炎症因子、肺功能的影响。方法 选取2020年1月-12月入院接受治疗的慢阻肺急性加重期患者68例，按照随机数字表法分为研究组和对照组，各34例，对照组采用特布他林雾化治疗，研究组采用糖皮质激素联合特布他林雾化治疗，比较两组临床疗效、炎症因子水平[白细胞介素-6（IL-6）、C-反应蛋白（CRP）]、肺功能[第1 s用力肺活量（FEV1）、用力肺活量（FVC）、最大呼气中段流量（MMEF）、呼气峰流速（PEF）]、血气功能[动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）、动脉血氧饱和度（SaO2）]及临床症状消退时间。结果 研究组总有效率为97.06%，高于对照组的76.47%，差异有统计学意义（P＜0.05）；研究组治疗后IL-6、CRP水平低于对照组，差异有统计学意义（P＜0.05）；研究组治疗后FEV1、FVC、MMEF、PEF均优于对照组，差异有统计学意义（P＜0.05）；研究组治疗后PaO2、PaCO2、SaO2均优于对照组，差异有统计学意义（P＜0.05）；研究组喘息缓解时间、咳嗽消失时间、哮鸣音基本消失时间均低于对照组，差异有统计学意义（P＜0.05）。结论 采用糖皮质激素联合特布他林雾化治疗慢阻肺急性加重期患者的总有效率更高，同时，有利于缓解患者机体炎症反应，加快肺功能和血气功能恢复，缩短临床症状缓解时间，具有较高的临床应用价值。
Abstract:
Objective To study the efficacy of glucocorticoid combined with terbutaline atomization in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on inflammatory factors and lung function.Methods A total of 68 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to hospital from January to December 2020 were selected and divided into study group and control group according to the random number table method, with 34 cases in each group. The control group was treated with terbutaline atomization, and the study group was treated with glucocorticoid combined with terbutaline atomization. The clinical efficacy, levels of inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP)], pulmonary function [forced vital capacity in the first second (FEV1), forced vital capacity (FVC), maximum mid-expiratory flow (MMEF), peak expiratory flow rate (PEF)], blood gas function [partial pressure of arterial oxygen (PaO2), partial pressure of arterial carbon dioxide (PaCO2), arterial oxygen saturation (SaO2)] and clinical symptom regression time were compared between the two groups.Results The total effective rate of the study group was 97.06%, which was higher than 76.47% of the control group, and the difference was statistically significant (P<0.05). The levels of IL-6 and CRP in the study group after treatment were lower than those in the control group, and the differences were statistically significant (P<0.05). FEV1, FVC, MMEF and PEF in the study group after treatment were better than those in the control group, and the differences were statistically significant (P<0.05). PaO2, PaCO2 and SaO2 in the study group after treatment were better than those in the control group, and the differences were statistically significant (P<0.05). The wheezing remission time, cough disappearance time and wheezing sound disappearance time in the study group were lower than those in the control group, the differences were statistically significant (P<0.05).Conclusion The total effective rate of glucocorticoid combined with terbutaline atomization in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease is higher. At the same time, it is beneficial to alleviate the inflammatory response of patients, accelerate the recovery of lung function and blood gas function, and shorten the remission time of clinical symptoms. It has high clinical application value.

参考文献/References:

[1]李晓佳,张俊林,金雪梅,等.糖皮质激素联合特布他林治疗慢性阻塞性肺疾病急性加重期对肺功能及预后的影响[J].国际呼吸杂志,2016,36(5):346-349[2]高萍,曹殿凤,赵娜,等.硫酸特布他林雾化吸入联合机械排痰治疗尘肺合并慢性阻塞性肺疾病急性加重期的疗效观察[J].中国工业医学杂志,2017,30(5):346-347.[3]欧阳景根.噻托溴铵配合沙美特罗替卡松治疗慢阻肺急性加重期的作用评价[J].医学信息,2017,30(17):107-108.[4]唐晓霞,翁军,韩静.特布他林联合多索茶碱对慢性阻塞性肺疾病患者的疗效及患者呼吸动力学的影响[J].中国医院药学杂志,2020,40(15):1659-1662.[5]代岩,金博,姜乐.糖皮质激素联合特布他林治疗对慢阻肺急性加重期外周血单核细胞PD-1/PD-L1表达的影响[J].中国免疫学杂志,2019,35(13):1621-1626.[6]梁颖萍,柳爱梅.糖皮质激素联合特布他林治疗慢阻肺急性加重期的效果[J].中西医结合心血管病电子杂志,2019,7(21):30-31.[7]薛世民,高晓嵘,叶瑜,等.特布他林联合羧甲司坦片治疗慢性阻塞性肺疾病的疗效及对血清MMP-9,MMP-12,TIMP-1的影响[J].现代生物医学进展,2020,20(3):532-535,514.[8]王莉,汪诚,叶盛,等.特布他林联合噻托溴铵对慢性阻塞性肺疾病患者HIF1,γ-GCS水平的影响[J].疑难病杂志,2020,19(10):1009-1012.[9]刘晓冬,胡克.特布他林联合糖皮质激素与谷胱甘肽治疗慢阻肺急性加重期的疗效及对患者炎症因子水平的影响[J].河北医学,2020,26(1):71-75.[10]邢振川,郭华征,高芸菲.硫酸特布他林联合布地奈德混悬液雾化吸入治疗慢阻肺急性加重期的疗效及对血清PCT,IL-6,IFN-γ水平变化的影响[J].解放军预防医学杂志,2019,37(10):20-21.[11]谢兴旺,焦绪亮,刘传凤.糖皮质激素联合特布他林在慢阻肺急性加重期患者中的治疗效果评价[J].中外医学研究,2017,15(13):47-49.[12]胡志.观察糖皮质激素联合特布他林治疗慢阻肺急性加重期的疗效[J].黑龙江医药,2017,30(3):564-565.[13]陈元菁,王湘云,艾红军,等.雾化特布他林联合布地奈德治疗急性加重期慢性阻塞性肺疾病的临床疗效及对炎性因子的影响[J].山西医药杂志,2019,48(13):1531-1534.[14]蔡昕姝,薛运昕,谭明旗.布地奈德及特布他林联合噻托溴铵对老年慢性阻塞性肺疾病急性加重期患者肺功能的影响[J].中国老年学杂志,2020,40(6):1218-1220.[15]胡海涛,曾丽娟,屈磊,等.噻托溴铵联合吸入糖皮质激素对哮喘-慢阻肺重叠综合征患者肺功能,FeNO及免疫功能的影响[J].空军医学杂志,2017,33(2):113-117.[16]张卓红.吸入激素对哮喘-慢阻肺重叠综合征患者气道重塑及内皮细胞功能的影响[J].陕西医学杂志,2016,45(8):1040-1041,1042.[17]赵启文,侯欣,高芳.吸入性糖皮质激素在慢性阻塞性肺疾病急性加重期患者中的应用疗效分析[J]. 山西医药杂志,2020,49(18):2479-2481.[18]孙虎,左蕾,叶远征,等.全身应用糖皮质激素对慢性阻塞性肺疾病急性加重患者治疗效果的系统评价[J].中国呼吸与危重监护杂志,2017,16(1):1-8.[19]陈小军.布地奈德联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的疗效[J].医学信息,2020,33(6):154-155.[20]刘晓冬,胡克.特布他林联合糖皮质激素与谷胱甘肽治疗慢阻肺急性加重期的疗效及对患者炎症因子水平的影响[J].河北医学,2020,26(1):71-75.

相似文献/References:

[1]钟时嘉.亚急性甲状腺炎的临床分析[J].医学信息,2018,31(01):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
　ZHONG Shi-jia.Clinical Analysis of Subacute Thyroiditis[J].Journal of Medical Information,2018,31(23):181.[doi:10.3969/j.issn.1006-1959.2018.01.073]
[2]唐培渊,宋俊峰,秦克乐,等.难治性特发性血小板减少性紫癜的治疗进展[J].医学信息,2018,31(05):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
　TANG Pei-yuan,SONG Jun-feng,QIN Ke-le,et al.Progress in Treatment of Refractory Idiopathic Thrombocytopenic Purpura[J].Journal of Medical Information,2018,31(23):42.[doi:10.3969/j.issn.1006-1959.2018.05.016]
[3]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Journal of Medical Information,2018,31(23):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[4]康 凯,郑继伟,王 闰.糖皮质激素治疗甲亢伴浸润性突眼的疗效分析[J].医学信息,2018,31(08):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
　KANG Kai,ZHENG Ji-wei,WANG Run.Efficacy of Glucocorticoids in the Treatment of Hyperthyroidism with Infiltrating Exophthalmos[J].Journal of Medical Information,2018,31(23):103.[doi:10.3969/j.issn.1006-1959.2018.08.033]
[5]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(23):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[6]刘广涛,关凤军,董 晨.原发性肾病综合征患儿肾组织P-gp170蛋白和mRNA表达与临床病理及预后的关系[J].医学信息,2018,31(21):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
　LIU Guang-tao,GUAN Feng-jun,DONG Chen.Relationship between the Expression of p-gp170 Protein and mRNA in Renal Tissue of Children with Primary Nephrotic Syndrome and Clinical Pathology and Prognosis[J].Journal of Medical Information,2018,31(23):61.[doi:10.3969/j.issn.1006-1959.2018.21.017]
[7]陈晓霞,唐 勇,胡 庆,等.吗替麦考酚酯联合糖皮质激素治疗特发性膜性肾病的疗效观察[J].医学信息,2018,31(22):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
　CHEN Xiao-xia,TANG Yong,HU Qing,et al.Therapeutic Effect of Mycophenolate Mofetil Combined with Glucocorticoid on Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2018,31(23):89.[doi:10.3969/j.issn.1006-1959.2018.22.024]
[8]高 鹏,高 浩,燕 飞.坏疽性脓皮病1例[J].医学信息,2019,32(01):191.[doi:10.3969/j.issn.1006-1959.2019.01.063]
[9]马艳艳,刘建军.肌无力危象的治疗研究进展[J].医学信息,2019,32(06):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
　MA Yan-yan,LIU Jian-jun.Progress in the Treatment of Myasthenia Crisis[J].Journal of Medical Information,2019,32(23):45.[doi:10.3969/j.issn.1006-1959.2019.06.016]
[10]谢卫强,巩 栋,高明暄,等.关节病性银屑病伴髋关节结核1例[J].医学信息,2019,32(07):189.[doi:10.3969/j.issn.1006-1959.2019.07.062]

更新日期/Last Update: 1900-01-01